Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy

To the Editor—Maternal and neonatal tetanus is a significant cause of mortality, estimated to cause 180,000 deaths annually [1]. Since the mid-1970s, tetanus vaccination of pregnant women has been included in the World Health Organization’s (WHO) Expanded Programme on Immunisation (EPI) [2]. Two doses of tetanus toxoid are sufficient to generate an antibody response (immunoglobulin G [IgG] class) capable of protecting neonates from tetanus, 3 doses are recommended for pregnancy, and 5 are recommended for life [3]. Despite these recommendations, WHO has identified a lack of longitudinal data quantifying antitetanus antibody boosting and duration during pregnancy following immunization in the EPI schedule [4].

To address this gap, we determined levels of antitetanus IgG at multiple time points from enrollment to delivery (median, 30 weeks of follow-up) in 376 pregnant women participating in malarial antibody studies at the antenatal clinics of the Shoklo Malaria Research Unit in northwest Thailand (previously published with ethics statement in Fowkes et al [5]). The tetanus vaccination regimen (tetanus toxoid) followed EPI guidelines [3]: dose 1, as early as possible during pregnancy; dose 2, one month after dose 1; dose 3, 6 months after dose 2; dose 4, 1 year after dose 3; and dose 5, one year after dose 4. During the study, 48.9% of women received their first dose, 86.2% received doses 2–4, and 8.2% received the final dose (dose 5).

The boosting and decay of tetanus antibody levels after vaccination was vaccine dose-dependent (Figure 1). In the first 8 days after vaccination, antitetanus IgG increased rapidly at comparable rates in all vaccination groups (P > .85 relative to T1). Interestingly, at 8 days after vaccination, IgG responses peaked and then plateaued in those receiving ≥2 doses. In contrast, IgG responses in those receiving their first vaccination peaked later at 50 days after vaccination (Figure 1, P < .001). After 50 days post-vaccination, antitetanus IgG responses declined and calculated IgG half-life was dependent on vaccination dose: 7.12 years (95% confidence interval [CI], 3.02–∞) for dose 1; 10.97 years (6.71–∞) for doses 2–4; and 12.28 years (6.15–∞) for dose 5. These estimates are in concordance with published nondose-specific half-life estimates in nonpregnant American women (10 years, 95% CI, 8–14) [6].

The close consecutive sampling of antitetanus antibody levels has allowed us to define, in the greatest detail to date, antitetanus IgG kinetics postvaccination, and we provide the first estimates of tetanus IgG half-lives in pregnancy according to vaccination dose in the EPI schedule. These data are important for predicting protection in neonates and are invaluable for understanding the sustainability of protective humoral immunity in high-risk populations such as pregnant women in resource-poor settings.

Figure 1. Antitetanus immunoglobulin G (IgG) after vaccination in 376 pregnant women according to vaccination dose. Tetanus IgG levels (optical density) were determined by enzyme-linked immunosorbent assay as previously described [5] with tetanus toxoid coated at 0.4 colony-forming units/mL and sera tested at a 1:500 dilution. Lines represent predicted mean tetanus IgG levels (calculated by mixed linear models with random effect for the intercept, slope, and covariance). The best-fit model had linear splines placed at 8 and 50 days, and each vaccination category had its own slope for antibody level over time since vaccination. Analysis was unadjusted because other potential confounders including gravidity, trimester, chloroquine prophylaxis [7], and Plasmodium species infection [8] did not significantly alter the model outputs. Abbreviations: IgG, immunoglobulin G; OD, optical density.
Acknowledgments. We thank the participants and the Karen staff of the Shoklo Malaria Research Unit (SMRU) and Nadia Cross and Gaoqian Feng for technical assistance. We also thank CSL Limited, Australia, for kindly providing tetanus toxoid.

Disclaimer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Financial support. This work was supported by the National Health and Medical Research Council of Australia (program grant to J. G. B.; training award to F. J. I. F.; Infrastructure for Research Institutes Support Scheme Grant), Australian Research Council (Future Fellowship to J. G. B.), and Victorian State Government Operational Infrastructure Support grant. SMRU is part of the Mahidol Oxford University Tropical Medicine Research Unit supported by the Wellcome Trust of Great Britain.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


Correspondence: Freya Fowkes, DPhil, Macfarlane Burnet Institute of Medical Research, 85 Commercial Rd, Melbourne, VIC 3004, Australia (fowkes@burnet.edu.au).

Clinical Infectious Diseases 2013;56(5):749–50
© The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1093/cid/cis979